Brown et al. [51] showed that mesalamine, a mainstay therapeutic agent for UC, decreases the expression of Akt-phosphorylated β-catenin on intestinal crypts of UC patients and in an animal model of intestinal chronic inflammation (IL-10−/−). The gene discussed is AKT1; the disease is inflammatory response.